AR051108A1 - Compuesto de 4- heteroaril- metil o 4-(heteroaril - metil substituido ) - imidazol2- tiona y su uso para preparar una coposicion farmaceutica - Google Patents

Compuesto de 4- heteroaril- metil o 4-(heteroaril - metil substituido ) - imidazol2- tiona y su uso para preparar una coposicion farmaceutica

Info

Publication number
AR051108A1
AR051108A1 ARP050103995A ARP050103995A AR051108A1 AR 051108 A1 AR051108 A1 AR 051108A1 AR P050103995 A ARP050103995 A AR P050103995A AR P050103995 A ARP050103995 A AR P050103995A AR 051108 A1 AR051108 A1 AR 051108A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently selected
substituted
carbocyclic
pain
Prior art date
Application number
ARP050103995A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR051108A1 publication Critical patent/AR051108A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)

Abstract

Un compuesto de 4-heteroaril-metil- o 4-(heteroaril-metil substituido)-imidazol-2-tiona de la formula (|1) donde m, n y q son enteros seleccionados de 0 , 1, 2, 3 y 4 con la condicion de que la suma de m, n y q sea 1, 2, 3 o 4; W, X e Y representan un CV o un heteroátomo independientemente seleccionados de N, O y S con la condicion de que al menos uno de los grupos mencionados W, X e Y representan un heteroátomo, las líneas punteadas representan una union o ausencia de una union con la condicion de que no haya más de 3 líneas punteadas presentes en el anillo y con la posterior condicion que ninguna línea punteada representando una union está conectada a un heteroátomo de O o de S; R1 es independientemente H, alquilo C1-4, F alquilo sustituido C1-4, (CH2)sCN, (CH2)s-OR2, (CH2)s-NR4R5, s es un entero seleccionado de 1, 2 y 3; R2 está independientemente H, alquilo C1-4, C(O)R8, arilo carbocíclico o arilo heterocíclico, que tiene 1 hasta 3 heteroátomos independientemente seleccionados de N, O y S; p es un entero seleccionado de 0, 1, 2, 3, 4, y 5; R3 es independientemente seleccionado de los grupos que consisten de alquilo C1-4, F alquilo substituido C1-4, alquenilo C2-4, alquinilo C2-4, F, Cl, Br, Y, N3, NO2, (CH2)t-OR2, (CH2)t-NR5R6, (CH2)t-CN, C(O)R4, C(O)OR4, (CH2)t-SO2R4, arilo carbocíclico o arilo heterocíclico que tiene 1 hasta 3 heteroátomos independientemente seleccionados de N, O y S; t es un entero seleccionado de 0, 1, 2 y 3; R4 y R5 son independientemente H o alquilo C1-4; R6 es independientemente H, alquilo C1-4, arilo carbocíclico o arilo heterocíclico que tiene 1 hasta 3 heteroátomos independientemente seleccionados de N, O y S. Opcionalmente R7 y R8 junto con los átomos a los que están unidos conjuntamente forman un anillo carbocíclico o heterocíclico, el anillo heterocíclico que tiene 5 o 6 átomos en el anillo y 1 hasta 3 heteroátomos independientemente seleccionados de N, O y S; dicho anillo carbocíclico o heterocíclico conjuntamente formado por R7 y R8 siendo opcionalmente substituidos con los grupos R9 desde 1 hasta 7; R9 está independientemente seleccionado de los gripos que consisten de alquilo C1-4, alquenilo C2-4, alquinilo C2-4, CH2OR2, CH2N(R2)2, CH2CN, C(O)R2, C(O)OR6, SO3R6, SO2N(R2)2, CH2SR2, F, Cl, Br, I, F alquilo sustituido C1-4, CN, N3, NO2, N(R2)2, OR2, SR2 o R8 es O o S unido doble a un C de dicho anillo carbocíclico o heterocíclico, con la condicion de que el anillo de formula (2) no representa un imidazol, un imidazol substituido, una furanona o 2-furanona substituido. Son agonistas de receptores adrenérgicos alfa2 y algunos no tienen o tienen mínima actividad cardiovascular y/o sedante. Son utiles para el tratamiento del dolor y otras condiciones con efectos secundarios mínimos. Su uso para preparar una composicion farmacéutica util para tratar dolor cronico, dolor visceral, dolor neuropático, dolor en la cornea, glaucoma, presion intraocular elevada, neuropatías isquémicas, , enfermedades neurodegenerativas, diarrea, congestion nasal, espasticidad muscular, diuresis, síndrome de abstinencia, neuropatía optica, isquemia espinal, derrame cerebral, déficit de la memoria y del conocimiento, desordenes de déficit de atencion, psicosis, desordenes maníacos, ansiedad, depresion, hipertension, falla cardíaca congestiva, isquemia cardíaca, artritis, espondilitis, artritis gotosa, osteoartritis, artritis juvenil, enfermedades autoinmunes, lupus eritematoso, inflamaciones gastrointestinales cronicas, enfermedad de Crohn, gastritis, síndrome del intestino irritable (IBS), dispepsia funcional o colitis ulcerosa.
ARP050103995A 2004-09-24 2005-09-26 Compuesto de 4- heteroaril- metil o 4-(heteroaril - metil substituido ) - imidazol2- tiona y su uso para preparar una coposicion farmaceutica AR051108A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61294504P 2004-09-24 2004-09-24

Publications (1)

Publication Number Publication Date
AR051108A1 true AR051108A1 (es) 2006-12-20

Family

ID=35636634

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103995A AR051108A1 (es) 2004-09-24 2005-09-26 Compuesto de 4- heteroaril- metil o 4-(heteroaril - metil substituido ) - imidazol2- tiona y su uso para preparar una coposicion farmaceutica

Country Status (9)

Country Link
US (2) US7399868B2 (es)
EP (1) EP1791832A1 (es)
JP (1) JP2008514603A (es)
AR (1) AR051108A1 (es)
AU (1) AU2005290008A1 (es)
BR (1) BRPI0516025A (es)
CA (1) CA2581828A1 (es)
TW (1) TW200624430A (es)
WO (1) WO2006036507A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008514603A (ja) * 2004-09-24 2008-05-08 アラーガン、インコーポレイテッド α２アドレナリン作動剤としての４−（ヘテロアリール−メチルおよび置換ヘテロアリール−メチル）−イミダゾール−２−チオン
US8003624B2 (en) * 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
CN101374830A (zh) * 2005-08-25 2009-02-25 先灵公司 α2C肾上腺素受体激动剂
ATE517883T1 (de) * 2005-08-25 2011-08-15 Schering Corp Imidazolderivate als funktionelle selektive agonisten des alpha2c-adrenorezeptors
JP2010510184A (ja) * 2006-11-16 2010-04-02 エフ．ホフマン−ラ ロシュ アーゲー 置換４−イミダゾール類
WO2008088937A1 (en) * 2007-01-12 2008-07-24 Allergan, Inc. Quinolynylmethylimidizoles as therapeutic agents
US7868020B2 (en) 2007-01-12 2011-01-11 Allergan, Inc. Quinolynylmethylimidizoles as therapeutic agents
US8013169B2 (en) 2007-01-12 2011-09-06 Allergan, Inc Naphthylmethylimidizoles as therapeutic agents
AU2008251324B2 (en) * 2007-05-14 2014-05-01 Allergan, Inc. ((Phenyl)imidazolyl)methylheteroaryl compounds
WO2009052072A1 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
US8455548B2 (en) * 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US7902247B2 (en) * 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
WO2009105504A2 (en) * 2008-02-21 2009-08-27 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
BRPI0912604A2 (pt) * 2008-05-13 2019-09-10 Allergan Inc quinolinilmetilimidazóis como agentes terapêuticos
CA2728480A1 (en) * 2008-07-24 2010-01-28 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl derivatives
US20120028940A1 (en) * 2008-09-16 2012-02-02 Merck Sharp & Dohme Corp. Functionally selective azanitrile alpha-2c adrenoreceptor agonists
JP2012517433A (ja) * 2009-02-06 2012-08-02 アラーガン インコーポレイテッド アルファ２ｂおよび／またはアルファ２ｃアドレナリンレセプターのサブタイプ選択的モジュレーターとしてのピリジン化合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1122111A (en) * 1913-06-21 1914-12-22 Andrew Hanson Measuring-pump.
SU795462A3 (ru) 1975-03-14 1981-01-07 Эдьт Дьедьесерведьесети Дьяр (Фирма) Способ получени тиокарбамидныхпРОизВОдНыХ
US4564666A (en) * 1985-03-11 1986-01-14 Desoto, Inc. Urethane acrylates based on polyepichlorohydrin polyether diols and optical fiber coatings based thereon
US4798843A (en) 1987-07-09 1989-01-17 Smithkline Beckman Corporation 2-mercaproimidazole dopamine-β-hydroxylase inhibitors
JPH0667368B2 (ja) 1989-12-15 1994-08-31 株式会社サンシール 掃除機内の殺菌、防虫、脱臭方法
JPH0667368A (ja) 1992-08-13 1994-03-11 Fuji Photo Film Co Ltd 黒白ハロゲン化銀写真感光材料の現像方法
US5646664A (en) * 1995-01-18 1997-07-08 Hewlett-Packard Company Ink container valving
US6465466B1 (en) * 1995-12-22 2002-10-15 Leif J. I. Lundblad Uses of indolo-2 [2,3b] -quinoxalines
ZA971896B (en) * 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
BR9710002A (pt) 1996-06-27 1999-08-10 Janssen Pharmaceutica Nv N-[4-(heteroarilmetil)fenil]-heteroarilaminas
EP1038786A4 (en) 1997-11-28 2009-04-08 Mitsubishi Plastics Inc HANDLE FOR PLASTIC LASER AND BOTTLE WITH HANDLE
RU2235092C2 (ru) 1997-12-04 2004-08-27 Оллерган Инк. Замещенные производные имидазола, способ введения активного соединения и способ лечения на основе этих соединений
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6545182B2 (en) 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
JP2002097310A (ja) 2000-09-25 2002-04-02 Bridgestone Corp タイヤ
JP2002097312A (ja) 2000-09-26 2002-04-02 Bridgestone Corp タイヤ
WO2002058730A2 (en) 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US6534542B2 (en) 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
US7323485B2 (en) * 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
JP2008514603A (ja) * 2004-09-24 2008-05-08 アラーガン、インコーポレイテッド α２アドレナリン作動剤としての４−（ヘテロアリール−メチルおよび置換ヘテロアリール−メチル）−イミダゾール−２−チオン

Also Published As

Publication number Publication date
TW200624430A (en) 2006-07-16
JP2008514603A (ja) 2008-05-08
AU2005290008A1 (en) 2006-04-06
BRPI0516025A (pt) 2008-08-19
US20080221152A1 (en) 2008-09-11
WO2006036507A1 (en) 2006-04-06
US7399868B2 (en) 2008-07-15
US20060069143A1 (en) 2006-03-30
EP1791832A1 (en) 2007-06-06
CA2581828A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
AR051108A1 (es) Compuesto de 4- heteroaril- metil o 4-(heteroaril - metil substituido ) - imidazol2- tiona y su uso para preparar una coposicion farmaceutica
AR051106A1 (es) Compuesto de 4- (metil ciclico condensado) - imidazol - 2- tiona y su uso para la preparacion de una composicion farmaceutica
RU2318816C2 (ru) 4-замещенные имидазол-2-тионы и имидазол-2-оны в качестве агонистов альфа2b- и альфа2c- адренергических рецепторов
AR051107A1 (es) Compuesto de 4- (fenilmetil - metil) o 4 (fenilmetil- metil substituido ) - imidazol 2-tiona y su uso para la preparacion de una composicion farmaceutica
MX2020001777A (es) Compuestos novedosos.
MX2020011501A (es) Compuestos novedosos.
EA200600364A1 (ru) Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора
EA200701640A1 (ru) Новые соединения с терапевтическим эффектом
ATE415160T1 (de) Modulatoren von peroxisome proliferator- aktivierten rezeptoren
MA30355B1 (fr) Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3
ES2678086T3 (es) Compuestos de diona cíclicos (alquil-fenil)-sustituidos activos como herbicidas y derivados de los mismos
PE20071254A1 (es) Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion
EA201890509A1 (ru) Сополимер, используемый в качестве моющей присадки к топливу
PE20081508A1 (es) Derivados de indol y de benzofurano-2-carboxamida
RU2007148224A (ru) Производные пиперидин-4-иламида и их применение в качестве антагонистов рецептора sst подтипа 5
RU2009136996A (ru) Трициклические соединения, которые можно использовать для лечения нарушений, связанных с анормальным уровнем содержания железа в организме
MA41633A (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
RU2008150616A (ru) Производные 5-фенилтиазол-2-илмочевины и применение в качестве ингибиторов киназы pi3
PE20120732A1 (es) Agonistas del receptor de esfingosina-1-fosfato
RU2017102513A (ru) Соль гетероциклического соединения, замещенного галогеном
PE20080191A1 (es) Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6
PE20040959A1 (es) Derivados de acido acetico sustituido con cicloalquilmetoxi y procedimientos para su preparacion
AR050960A1 (es) Uso de un compuesto de 4-bencil-1,3-dihidro-imidazol-2-tiona sustituido o no sustituido para la preparacion de una composicion farmaceutica y dichos compuestos
EA201290534A1 (ru) Бициклические тиазолы в качестве аллостерических модуляторов mglur5 рецепторов
MA38659A1 (fr) Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal